Welcome to our dedicated page for Hologic SEC filings (Ticker: HOLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Hologic, Inc. filings document the company’s transition from a Nasdaq-listed public issuer to a private company after its completed acquisition by funds managed by Blackstone and TPG. The record includes Form 25 notice for removal of Hologic common stock from Nasdaq listing and Form 15 certification to terminate registration or suspend Exchange Act reporting duties for its common stock.
Related 8-K disclosures cover material events, merger-related agreements and shareholder voting matters, capital-structure disclosures, governance and compensation arrangements, operating results, and clinical or regulatory developments tied to Hologic’s women’s health medical-technology business.
Hologic director Stacey D. Stewart reported an equity grant of 3,190 restricted stock units on February 26, 2026. The award has no cash exercise price and will vest on the date of the 2027 Annual Meeting of Stockholders, then be settled in shares of common stock.
After this grant, Stewart directly holds 8,358 shares and units in total, including 3,436 restricted stock units whose settlement has been deferred under Hologic’s Deferred Equity Plan.
Stamoulis Christiana reported acquisition or exercise transactions in this Form 4 filing.
Hologic Inc. director Christiana Stamoulis reported an equity award of 3,190 restricted stock units (RSUs) of common stock. The RSUs were granted at no cash purchase price and will vest on the date of Hologic’s 2027 Annual Meeting of Stockholders.
Each restricted stock unit will be settled in one share of Hologic common stock on a one-for-one basis. After this award, Stamoulis directly holds 50,526 shares of Hologic common stock, reflecting her updated ownership position as reported in the filing.
Hologic Inc. director Nanaz Mohtashami received an equity award in the form of restricted stock units. On the reported date, she acquired 3,190 RSUs at no cash cost, classified as a grant or award acquisition. Following this grant, she now holds 7,371 shares of common stock in direct ownership.
The footnotes explain that these RSUs will vest on the date of Hologic’s 2027 Annual Meeting of Stockholders and will be settled in shares of common stock on a one-for-one basis, linking director compensation directly to future stock performance.
McMillan Wayde D. reported acquisition or exercise transactions in this Form 4 filing.
Hologic, Inc. director Wayde D. McMillan reported receiving an equity award of 3,190 restricted stock units of common stock. The award was granted at no cash cost per share and will vest on the date of Hologic’s 2027 Annual Meeting of Stockholders.
Each restricted stock unit will be settled in one share of Hologic common stock upon vesting. Following this grant, McMillan’s directly held common stock position increased to 4,932 shares, reflecting his equity-based alignment with shareholders.
Madaus Martin D reported acquisition or exercise transactions in this Form 4 filing.
Hologic director Martin D. Madaus reported an equity award of 3,190 restricted stock units of common stock on February 26, 2026. These units vest on the date of the 2027 Annual Meeting of Stockholders and are settled one-for-one in Hologic common shares.
After this grant, Madaus directly holds 5,396 common shares. A separate line shows indirect ownership of 5,445 common shares through a revocable trust, reflecting his holdings in that entity.
Hologic director Ludwig Hantson received an equity award in the form of restricted stock units. On the reported date, he was granted 3,190 RSUs tied to Hologic common stock at no cash cost, classified as a grant or award acquisition. These RSUs are scheduled to vest on the date of the 2027 Annual Meeting of Stockholders and will be settled one-for-one in shares of common stock. After this award, Hantson’s directly held stake is 16,146 shares, which includes 3,695 RSUs whose settlement has been deferred under Hologic’s Deferred Equity Plan.
Hologic Inc. director Charles J. Dockendorff acquired 3,190 restricted stock units of common stock as a grant. The award was recorded at a price of $0.0000 per share, reflecting a stock-based compensation grant rather than a market purchase.
These restricted stock units vest on the date of Hologic’s 2027 Annual Meeting of Stockholders and are settled in shares of common stock on a one-for-one basis. After this grant, Dockendorff directly holds 6,626 shares of common stock, and indirectly holds 15,370 shares through a revocable trust.
T. Rowe Price Investment Management, Inc. filed an amended Schedule 13G reporting its beneficial ownership of Hologic, Inc. common stock as of December 31, 2025.
The firm reports beneficial ownership of 5,932,301 shares of Hologic common stock, representing 2.7% of the class. It has sole power to vote 5,914,773 shares and sole power to dispose of 5,932,301 shares, with no shared voting or dispositive power.
The filer states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Hologic. It also expressly denies that this filing should be construed as an admission of beneficial ownership of the reported securities.
Hologic executive Mark W. Horvath, President of Breast & Skeletal Health, reported a small administrative share disposition related to taxes. On February 10, 2026, 113 shares of common stock were withheld at $75.15 per share to cover tax obligations from settling restricted stock units.
After this tax-withholding transaction, Horvath directly beneficially owns 23,026 shares of Hologic common stock. This total includes 4,605 performance stock units/restricted stock units whose settlement has been deferred under Hologic’s Deferred Equity Plan.
Hologic, Inc. reported results from a special shareholder meeting held to vote on its proposed acquisition by affiliates of funds managed by Blackstone Inc. and TPG Global, LLC. Shareholders approved the Merger Agreement, with 178,777,739 votes for, 151,271 against and 117,121 abstaining.
On the record date, 223,065,562 shares were entitled to vote, and 179,046,131 shares, or about 80.27% of voting power, were present, establishing a quorum. An advisory, non‑binding proposal on potential executive compensation related to the merger was not approved, with 60,764,502 votes for and 115,723,408 against.
Because the merger proposal passed, no adjournment vote was needed. The merger is expected to close in March or April 2026, subject to required regulatory approvals and other customary closing conditions.